Tharimmune (Tharimmune) Total Current Assets : $8.89 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Tharimmune Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Tharimmune's total current assets for the quarter that ended in Mar. 2024 was $8.89 Mil.

Tharimmune Total Current Assets Historical Data

The historical data trend for Tharimmune's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tharimmune Total Current Assets Chart

Tharimmune Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

0.04

0.30

0.62

6.69

10.95

Tharimmune Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial												4.72	4.60	3.17	10.95	8.89

Tharimmune Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Tharimmune's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	10.935	+	0	+	0	+	0.010999999999999
	=	10.95

Tharimmune's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	8.427	+	0	+	0	+	0.46
	=	8.89

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Tharimmune (NAS:THAR) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Tharimmune's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.427	-	1.838	+	0.75 * 0	+	0.5 * 0
=	6.59

Tharimmune Total Current Assets Related Terms

Thank you for viewing the detailed overview of Tharimmune's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Tharimmune (Tharimmune) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tharimmune Inc (NAS:THAR) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1200 Route 22 East, Suite 2000, Bridgewater, NJ, USA, 08807

Website

https://www.hillstreambio.com

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors.

Executives

Randy Milby	director, officer: Chief Executive Officer	5 JACK LANE, NEWARK DE 19711
Kelly Anderson	director	C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
Leonard L Mazur	director	C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Sandeep Laumas	10 percent owner	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Thomas Hess	officer: Chief Financial Officer	366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Sireesh Appajosyula	director	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Lynne A. Bui	director	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Surender Kharbanda	10 percent owner	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Highpoint Pharmaceuticals Llc	10 percent owner	16192 COASTAL HIGHWAY, LEWES DE 19958
Kufe Llc	10 percent owner	179 GROVE STREET, WELLESLEY MA 02482
Varinder Kaur	10 percent owner	1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807